MX2022011498A - Formulacion liquida de gm-csf para inhalacion. - Google Patents

Formulacion liquida de gm-csf para inhalacion.

Info

Publication number
MX2022011498A
MX2022011498A MX2022011498A MX2022011498A MX2022011498A MX 2022011498 A MX2022011498 A MX 2022011498A MX 2022011498 A MX2022011498 A MX 2022011498A MX 2022011498 A MX2022011498 A MX 2022011498A MX 2022011498 A MX2022011498 A MX 2022011498A
Authority
MX
Mexico
Prior art keywords
csf
inhalation
liquid formulation
rhgm
nebulization
Prior art date
Application number
MX2022011498A
Other languages
English (en)
Spanish (es)
Inventor
Lars Skriver
Alan Watts
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of MX2022011498A publication Critical patent/MX2022011498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022011498A 2020-03-17 2021-03-17 Formulacion liquida de gm-csf para inhalacion. MX2022011498A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990810P 2020-03-17 2020-03-17
EP20164648 2020-03-20
PCT/EP2021/056851 WO2021185921A1 (en) 2020-03-17 2021-03-17 Liquid formulation of gm-csf for inhalation

Publications (1)

Publication Number Publication Date
MX2022011498A true MX2022011498A (es) 2022-10-07

Family

ID=74871418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011498A MX2022011498A (es) 2020-03-17 2021-03-17 Formulacion liquida de gm-csf para inhalacion.

Country Status (12)

Country Link
US (1) US20230201307A1 (enExample)
EP (1) EP4121000A1 (enExample)
JP (2) JP7631358B2 (enExample)
KR (1) KR102874958B1 (enExample)
CN (1) CN115297844A (enExample)
AU (1) AU2021237761B2 (enExample)
BR (1) BR112022018501A2 (enExample)
CA (1) CA3168421A1 (enExample)
IL (1) IL295406A (enExample)
MX (1) MX2022011498A (enExample)
WO (1) WO2021185921A1 (enExample)
ZA (1) ZA202209002B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120324338A (zh) * 2025-06-10 2025-07-18 厦门特宝生物工程股份有限公司 一种重组人粒细胞巨噬细胞刺激因子注射用液体制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141970A1 (en) 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
CN100394981C (zh) * 2005-09-16 2008-06-18 深圳市孚沃德生物技术有限公司 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation

Also Published As

Publication number Publication date
JP2025090573A (ja) 2025-06-17
WO2021185921A1 (en) 2021-09-23
JP7631358B2 (ja) 2025-02-18
BR112022018501A2 (pt) 2022-10-25
US20230201307A1 (en) 2023-06-29
CA3168421A1 (en) 2021-09-23
NZ791835A (en) 2025-10-31
AU2021237761B2 (en) 2026-02-05
CN115297844A (zh) 2022-11-04
KR102874958B1 (ko) 2025-10-21
KR20220154214A (ko) 2022-11-21
JP2023517480A (ja) 2023-04-26
IL295406A (en) 2022-10-01
EP4121000A1 (en) 2023-01-25
ZA202209002B (en) 2025-11-26
AU2021237761A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2022011498A (es) Formulacion liquida de gm-csf para inhalacion.
TWD187858S (zh) 呼吸回路之插管接頭
TWD215802S (zh) 鼻管組合
NZ765662A (en) Custom patient interface and methods for making same
EP4596015A3 (en) Patient interface and aspects thereof
TWD211069S (zh) 觸片
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
MX2021012723A (es) Inhalador de presión positiva para entrega de medicamento inhalable y métodos para uso.
TWD206800S (zh) 錶
BR112014029538A2 (pt) composição farmacêutica sólida, e, método para estabilizar um composto
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
GB2546949A (en) Substance delivery arrangement for gas therapy device
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
TWD220700S (zh) 頭戴式顯示器
TWD230485S (zh) 醫療用鼻管總成
BR112014000275A2 (pt) formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat)
EP4353288A3 (en) Internal cannula mounted nebulizer
MX2017015665A (es) Dispositivo de reanimacion cardiopulmonar por pulsos de presion positiva.
MX2022010193A (es) Moleculas dirigidas a proteina ras.
TWD210914S (zh) 用於呼吸設備之液體容室
CA227224S (en) Inhaler
TWD207252S (zh) 錶
CO2022008835A2 (es) Agonistas del tlr7
EP4243794A4 (en) TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL
GB202216949D0 (en) Dual mode negative pressure source operation for provision of negative pressure wound therapy